SEC Form 4 · accession 0001628280-18-012608
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Erik Zavodnick
Officer — CCO & President,
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 6:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 15, 2018 | F | 7,093 | $23.94 | D | 96,407 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered by Mr. Zavodnick to the Issuer on October 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award ("RSA") for 95,000 shares. The RSA vests in four equal annual installments from October 15, 2017, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.